Silence Therapeutics plc SLN · Stock Open Silence Therapeutics plc in new tab
Silence Therapeutics plc Analysis (SLN)
Is Silence Therapeutics plc a good investment? Silence Therapeutics plc (SLN) is currently trading at 10.68 USD. Market analysts have a consensus price target of 29.17 USD. This suggests a potential upside from current levels.
Earnings Schedule: Silence Therapeutics plc is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.39.
Investor FAQ
Does Silence Therapeutics plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Silence Therapeutics plc?
Silence Therapeutics plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.62.
Company Profile
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Community Discussion